ArticleExperimental & molecular medicine2026
Drp1 in M1 layer V GABAergic neurons orchestrates rTMS-mediated motor restoration and analgesia after spinal cord injury.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Spinal cord injury (SCI) leads to chronic motor and sensory deficits, with progressive secondary neurodegeneration posing a major therapeutic challenge. Although high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) over the primary motor cortex (M1) shows therapeutic potential, its underlying cellular mechanisms remain poorly understood. This translational study first demonstrated that HF-rTMS concurrently improved motor function and alleviated neuropathic pain in retrospective clinical cohorts and a validated murine SCI model. To decipher the supraspinal mechanism, we used an integrated approach combining behavioral analyses, transmission electron microscopy and single-nucleus RNA sequencing. Transcriptomics revealed that HF-rTMS specifically rescued SCI-induced disruptions in oxidative phosphorylation and mitochondrial energy metabolism pathways within M1 GABAergic neurons. Here we pinpointed a key molecular lesion: SCI selectively downregulated the mitochondrial fission regulator Drp1 in M1 layer V GABAergic neurons, leading to dysfunctional mitochondrial dynamics and bioenergetic deficits. HF-rTMS restored Drp1 levels and mitochondrial ultrastructure specifically in M1 but not in the primary somatosensory cortex, underscoring its region-selective action. Most importantly, functional causality was established: Drp1 overexpression in M1 GABAergic neurons mimicked the therapeutic benefits of HF-rTMS, whereas Drp1 knockdown or its pharmacological inhibition completely abolished these effects. Our findings establish impaired mitochondrial dynamics in a specific cortical microcircuit as a convergent driver of multisystem deficits post SCI, and identify Drp1 as a pivotal molecular target of HF-rTMS. This work provides a novel mechanistic foundation for Drp1-directed precision therapies, highlighting the potential of rescuing cortical mitochondrial bioenergetics to halt progressive secondary damage and improve functional recovery after central nervous system injury. This study demonstrates that high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) alleviates motor dysfunction and neuropathic pain after spinal cord injury (SCI). We show that HF-rTMS acts by upregulating the mitochondrial fission protein Drp1 specifically in layer V GABAergic neurons of the primary motor cortex. This restoration of Drp1 rescues impaired mitochondrial dynamics, normalizes associated proteins (VDAC-1 and Tom20) and recovers cellular energy (ATP) production. Consequently, rTMS reverses SCI-induced mitochondrial pathology, leading to substantial functional recovery. The therapeutic effect is dependent on Drp1, as its inhibition abolishes the benefits of HF-rTMS. Our findings reveal a precise neuromodulation mechanism targeting cortical mitochondrial homeostasis for treating SCI comorbidity.
Identifiers
42834110What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.